20 July 2021

Kuros to receive USD 7m up front and retain the potential to receive up to USD 166.5m in future revenues under a royalty purchase agreement with XOMA Corporation related to Kuros’s license agreement with Checkmate Pharmaceuticals. VISCHER has been advising Kuros Biosciences AG in Swiss law matters along the US lead counsel. The VISCHER team is led by Matthias Staehelin with Sebastian Flückiger (both Corporate/M&A).

Press release

Categories: Intellectual Property, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.